BioCentury | Jun 27, 2020
Deals

Who’ll buy uniQure now?

...after the deal was announced. UniQure received $450 million up front for rights to dezaparvovec (AMT-061...
BioCentury | Jun 25, 2020
Deals

June 24 Quick Takes: CSL pays $450M for uniQure’s hemophilia gene therapy; plus Merck-Yumanity, Editas, Compass-Olivia, Century-Empirica, Tetraphase-La Jolla

...is paying $450 million up front for an exclusive, worldwide license to commercialize etranacogene dezaparvovec (AMT-061...
BioCentury | Feb 12, 2020
Product Development

Freeline seeking ‘normal’ Factor IX activity via hemophilia gene therapy

...in hemophilia B patients in trials of FLT180a, fidanacogene elaparvovec from Pfizer and Roche and AMT-061...
...two therapies may be drawn once 52-week data are available from cohorts 2-4. Fidanacogene and AMT-061...
BioCentury | Sep 16, 2019
Financial News

Sept. 6 Financial Quick Takes: Turning Point, uniQure raise follow-ons; plus Autolus, Frequency, ADC

...will over-enroll the Phase III HOPE-B trial of its lead gene therapy candidate etranacogene dezaparvovec (AMT-061...
...TrkC (NTRK3) - Neurotrophic tyrosine kinase receptor 3 Hongjiang Li, Staff Writer and Paul Bonanos, Associate Editor AMT-061 FX-322 repotrectinib...
BioCentury | Aug 10, 2019
Product Development

Payers’ view of reimbursement when gene therapy isn’t enough

...testing for hemophilia B as well: fidanacogene elaparvovec (SPK-9001) from Pfizer Inc. and Spark, and AMT-061...
BioCentury | Jun 18, 2019
Company News

Latest twist in uniQure’s tale: possible sale

...deficiency therapy (see " uniQure Abandoning Glybera in Europe "). uniQure's most advanced gene therapy, AMT-061...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...is good news for smaller companies." Brad Loncar, Loncar Funds uniQure’s most advanced gene therapy AMT-061...
BioCentury | Mar 2, 2019
Product Development

Roche broadens its BD scope

...BMN 270) is in Phase III testing for hemophilia A. uniQure’s Factor IX gene therapy AMT-061...
BioCentury | Feb 13, 2019
Clinical News

uniQure gene therapy leads to sustained Factor IX activity in Phase IIb study

...new data showed sustained Factor IX activity in a Phase IIb study of gene therapy AMT-061...
...Activity Data for Hemophilia B Gene Therapy") . The open-label, single-arm, dose-confirmation study is evaluating AMT-061's...
...the data at the European Association for Haemophilia and Allied Disorders (EAHAD) meeting in Prague. AMT-061...
BioCentury | Feb 8, 2019
Clinical News

uniQure gets bump on latest hemophilia readout

...new data showed sustained Factor IX activity in a Phase IIb study of gene therapy AMT-061...
...Activity Data for Hemophilia B Gene Therapy" ). The open-label, single-arm, dose-confirmation study is evaluating AMT-061's...
...the data at the European Association for Haemophilia and Allied Disorders (EAHAD) meeting in Prague. AMT-061...
Items per page:
1 - 10 of 19